ClinicalTrials.gg
CompletedNCT04664634Updated Nov 5, 2026

A Digital Therapeutic Platform for Swallowing and Drooling Problems in Parkinson's

A Phase 3 interventional study of Aria Sensor in Dysphagia and Parkinson Disease, sponsored by Northwestern University. Completed at 1 site in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Northwestern University · Phase 3, Interventional, and Diagnostic

How we know

Updated Nov 5, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
59
Allocation
Not applicable
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 230 studies in Deglutition Disorders with a site in United States — 43 open to participants now, 48 under way, none of them phase 3. Deglutition Disorders · United States.

Enrollment
70th of 165
59 · median 50
Started
2025
with 8 others
Phase 3
6 of 230
none open now
Registered
156th of 230
by date

Among the 230 studies in Deglutition Disorders with a site in United States, this one is the 70th largest by enrollment of the 165 interventional ones that give a count, is one of 9 that started in 2025, is one of 6 in phase 3, and was the 156th registered.

Deglutition Disorders

875 studies on the registry are indexed under Deglutition Disorders; 237 are open to participants now.

Browse Deglutition Disorders studies →

Open to participants now

43 of the 230 studies in Deglutition Disorders with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 137 Deglutition Disorders studies recruiting now, 75 (55%) set no upper age limit and 26 (19%) stop at 75 or younger; 15 take children under 18; 20 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies in Deglutition Disorders with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is the development and early-stage validation of a wearable sensor for dysphagia in patients with PD.

Read the detailed description

The project goal is the development and early stage validation of a wearable sensor for dysphagia in patients with PD. The first phase of the program involves engineering goals relating to increasing the battery life of this sensor to 48 hours between charges and reducing the overall form factor size. The second phase of the program is to conduct focus groups with PD patients to assess sensor usability, set up burden, and design feedback. The third phase of the study will assess the feasibility of the sensor to detect and cue swallowing in a small cohort of PD patients.

03

Conditions studied

  • Dysphagia
  • Parkinson Disease
04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria. Age ≥22. English speaking. Diagnosis of idiopathic Parkinson's disease of any Hoehn and Yahr stage (I-V), determined by a neurologist.

Mild to moderate sialorrhea defined as a score of ≥ 11* on the Radboud Oral Motor Inventory for Parkinson's Disease (ROMP)-Saliva (C) subscale Subjects must be in the "on" phase of their medication during all study assessments. The "on" phase is defined as the period when the participant's medication is at peak effectiveness, minimizing motor fluctuations and enabling optimal motor function.

Study Exclusion Criteria. History of aspiration pneumonia within the past 12 months. Unable to swallow saliva without a maneuver. Actively receiving treatment for swallowing disorders or sialorrhea. Current alcohol/drug abuse. Diagnosed with neurological disorders other than PD. End stage dementia. History of head and neck cancer or surgery. Unable to demonstrate competency with the user-friendly sensor platform technology.

Known allergy to contrast material used during MBSS. Known allergy to sensor adhesive. Indwelling tracheostomy tube. Nasogastric (NG) feeding tube. Currently pregnant.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    Single Arm

    The Aria sensor is a wearable patch that continuously monitors physiological signals and provides vibratory haptic cues to increase swallow frequency. The intervention consists of using the sensor over a 3-week period, with active haptic cueing during Week 2 only.

    Device: Aria Sensor

Interventions

  • DeviceAria Sensor

    The Aria sensor is a wearable patch that continuously monitors physiological signals and provides vibratory haptic cues to increase swallow frequency. The intervention consists of using the sensor over a 3-week period, with active haptic cueing during Week 2 only.

06

What researchers measure

Primary outcomes

  1. Percent agreement with Gold Standard

    Percent agreement between experimental sensor Gold standard (GS) respiratory inductance plethysmography (RIP) with Inductotrace System®, Ambulatory Monitoring)

    Time frame: 1 year

  2. Change in mean swallow frequency during haptic cueing week

    This outcome measures the change in the average number of swallows per hour during the intervention week (Week 2, with haptic cueing) compared to baseline (Week 1, no cueing). Swallows will be manually labeled from sensor audio recordings by at least three independent annotators.

    Time frame: Week 1 to Week 2

Secondary outcomes

  1. Change in algorithm-detected swallow frequency during haptic cueing week

    This outcome measures the change in the mean swallow frequency as automatically detected by the Aria sensor's AI algorithm, comparing Week 2 (intervention) to Week 1 (baseline). Performance will be benchmarked against manually annotated swallows.

    Time frame: Week 1 to Week 2

  2. Change in Sialorrhea Clinical Scale for Parkinson's Disease (SCS-PD) score

    Assesses the effect of the intervention on drooling symptoms using the Sialorrhea Clinical Scale for PD. Participants complete this validated questionnaire at baseline, during, and after the intervention.

    Time frame: Baseline to Week 3

  3. Change in ROMP-Swallowing Subscale score

    Assesses changes in self-reported swallowing function using the Swallowing Subscale of the Radboud Oral Motor Inventory for Parkinson's Disease (ROMP). The ROMP is a validated, PD-specific measure.

    Time frame: Baseline to Week 3

  4. Change in participant adherence to haptic cueing

    Evaluates adherence to the intervention by quantifying the percentage of haptic cues that are followed by a swallow within 5 seconds during Week 2. Cue-swallow pairings are based on algorithmic and manual labeling.

    Time frame: Week 2

Other outcomes

  1. Change in Modified Barium Swallow Impairment Profile (MBSImP)

    Subsample of participants will undergo video fluoroscopy to evaluate swallowing function. The MBSImP scores will assess changes in swallow physiology pre- and post-intervention.

    Time frame: Baseline to Week 3

  2. Change in Penetration-Aspiration Scale Score

    Assesses airway protection during swallowing via penetration-aspiration scale scores from videofluoroscopic studies in a subsample of participants.

    Time frame: Baseline to Week 3

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2025 to primary completion in Oct 2026, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2020
First posted
Dec 11, 2020
StartActual
Apr 1, 2025
Primary completionActual
Oct 9, 2026
CompletionActual
Oct 9, 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 5, 2026
Primary completion
Oct 31, 2026→Oct 9, 2026 (actual)
Nov 5, 2026
Study completion
Oct 31, 2026→Oct 9, 2026 (actual)
Nov 5, 2026
Enrollment
60 (estimated)→59 (actual)
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Recruiting→Completed
    Primary completion Oct 31, 2026→Oct 9, 2026 (now actual)
    Study completion Oct 31, 2026→Oct 9, 2026 (now actual)
    Enrollment 60 (estimated)→59 (actual)
    + 5 other changes: verification date, responsible party, design details, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04664634
Responsible party
Sponsor
First posted
Dec 11, 2020
Start date
Apr 1, 2025
Primary completion
Oct 9, 2026
Completion
Oct 9, 2026
Last update
Nov 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion